PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis

ObjectivePulmonary hypertension (PH) in context with interstitial lung disease (ILD) portends serious clinical consequences and a high rate of mortality. Recently published randomized controlled trials (RCTs) which assessed the pulmonary arterial hypertension (PAH)-specific drugs for pulmonary hyper...

Celý popis

Podrobná bibliografie
Hlavní autoři: Ning Zhao, Jun Chen, Mingming Zhang, Lihui Zhou, Lisong Liu, Jie Yuan, Xingxue Pang, Dayi Hu, Xiaoxia Ren, Zhongyi Jin
Médium: Článek
Jazyk:English
Vydáno: Frontiers Media S.A. 2022-11-01
Edice:Frontiers in Cardiovascular Medicine
Témata:
pulmonary hypertension
interstitial lung disease
6-min walk distance (6MWD)
treprostinil
pulmonary arterial hypertension (PAH)
On-line přístup:https://www.frontiersin.org/articles/10.3389/fcvm.2022.992879/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.992879/full

Podobné jednotky